When tissue is severely damaged, surviving cells can respond in a concentrated burst of biological repair known as ...

Cells that are about to die send a signal to an executioner protein, but sometimes, those cells can fight back and regenerate ...

AbbVie and RemeGen are collaborating on RC148, a novel PD-1/VEGF-targeted bispecific antibody already being developed as a ...

A recent study links chemotherapy to impaired ovarian function and fertility through oxidative damage to ovarian follicles.

US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...

AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours: North Chicago, Illinois Tuesday, January 13, 2026, 14:00 Hrs ...

AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

A ₹3.5 crore Madhya Pradesh-funded study on cow dung and urine as cancer treatment raises questions over scientific validity, ...

The interferon regulatory factor (IRF) family of transcription factors, pivotal for initiating antiviral type I interferon ...

An antisense oligonucleotide has been shown to "collapse the entire oncogenic circuit" in pancreatic cancer, triggering ...

Chronic inflammation resulting from obesity is considered dangerous and leaves many confused about whether this actually ...